Surfactant protein-A in lung tissue obtained from patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006
Surfactant protein A (SP-A) and alveolar complement activation in patients at-risk for ARDS Source: Eur Respir J 2002; 20: Suppl. 38, 375s Year: 2002
Immunolocalization of surfactant protein-a (SP-A) in the lungs of pneumocystis pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009
Surfactant protein D as a potential serum marker of pulmonary emphysema Source: Annual Congress 2011 - Smoking-related disorders and smoking prevention Year: 2011
Association between the human surfactant protein-A (SP-A) gene locus and chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 583s Year: 2006
Serum surfactant protein D (SPD) as a specific marker for COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Surfactant protein-A serum level is associated with disease control and hospitalisation in patients with bronchial asthma Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010
Surfactant protein-B polymorphisms, pulmonary function and COPD in 10,231 individuals Source: Annual Congress 2010 - Genetics and risk factors for asthma and COPD Year: 2010
Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD Source: Annual Congress 2013 –COPD treatment and others Year: 2013
LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE) Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019
Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008
Early stage asymptomatic (HRCT detectable) patients with IPF showed augmented serum surfactant protein D (SP-D) Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002
Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009
The relationhip between serum levels of Surfactant protein D in COPD exacerbation severity and mortality Source: International Congress 2018 – Biomarkers of COPD Year: 2018
Differences in the immunolocalization of surfactant protein (SP)-A, SP-D and KL-6 in pulmonary alveolar proteinosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008
Bio-markers (KL-6, SP-D and SP-A) in drug-induced pneumonitis Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002
Oral presentation: Surfactant protein-B 121ins2 heterozygosity, reduced pulmonary function and COPD in smokers Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010
Serum Surfactant Protein D is decreased by oral steroids in asthma but not COPD Source: International Congress 2018 – Clinical determinants of asthma and biomarkers Year: 2018
Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects Source: Eur Respir J 2002; 20: 1152-1161 Year: 2002
Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis Source: Eur Respir J 2008; 31: 1197-1204 Year: 2008